Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;52(2):396-405.
doi: 10.4143/crt.2019.152. Epub 2019 Aug 28.

Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer

Affiliations

Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer

Jongseung Kim et al. Cancer Res Treat. 2020 Apr.

Abstract

Purpose: High rate of false-positive tests is a major obstacle to use human papillomavirus (HPV) detection as a diagnostic tool for high-grade squamous intraepithelial lesions or cervical cancer (HSIL+). We investigated whether type-specific viral load or physical state of HPV 16, 18, and 58 are useful biomarkers for HSIL+.

Materials and methods: Type-specific viral loads of E6 and E2 genes in cervical cells from 240, 83, and 79 HPV 16-, 18-, and 58-infected women, respectively, were determined using real-time polymerase chain reaction. Viral loads were normalized to cellular DNA (copy/cell). Total and integrated viral loads and physical state were compared between HSIL+ and controls, and diagnostic value was determined using receiver operating characteristic analysis.

Results: Viral loads of HPV 16, 18, and 58 were significantly different in lesions in the same pathologic grade. High type-specific total viral loads were significantly associated with HSIL+ (odds ratio [OR], 14.065, 39.472, and 7.103 for HPV 16, 18, and 58, respectively). High integrated viral load was related to HSIL+ in women with HPV 16 (OR, 8.242), and integrated state was associated with HSIL+ in women with HPV 18 (OR, 9.443). Type-specific total viral load was significantly associated with HSIL+ (area under curve, 0.914, 0.937, and 0.971 for HPV 16, 18, and 58, respectively), indicating an excellent performance in detecting HSIL+.

Conclusion: Type-specific total viral load may be a powerful diagnostic marker for HSIL+ in HPV 16-, 18-, and 58-infected HSIL+ lesions. If demonstrated in all other high-risk HPV types, this method can lead to a paradigm shift in the strategy of equivocal cytologic abnormalities.

Keywords: Cervical cancer; High-grade squamous intraepithelial lesions; Human papillomavirus; Viral load.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest relevant to this article was not reported.

Figures

Fig. 1.
Fig. 1.
Flowchart of the study subjects. Pap, Papanicolaou; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesions; HSIL+, high-grade squamous intraepithelial lesions or cervical cancer.
Fig. 2.
Fig. 2.
Type-specific normalized total viral load of human papillomavirus (HPV) 16, 18, and 58 in patients with cervical lesions at the same pathologic grade. Box plots show median and interquartile range. Controls include patients without pathologic abnormalities or with low-grade squamous intraepithelial lesions. p-values were evaluated using Kruskal-Wallis tests. HSIL, high-grade squamous intraepithelial lesions; ICC, invasive cervical cancer.
Fig. 3.
Fig. 3.
Receiver operating characteristic curve analysis of human papillomavirus (HPV) 16, 18, and 58 for the detection of high-grade squamous intraepithelial lesions or cervical cancer by type-specific total and integrated viral load. AUC, area under the curve.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796–802. - PubMed
    1. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11–22. - PubMed
    1. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385–94. - PubMed
    1. Ouh YT, Lee JK. Proposal for cervical cancer screening in the era of HPV vaccination. Obstet Gynecol Sci. 2018;61:298–308. - PMC - PubMed